# OnCo record paper-mirasol-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-mirasol-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-mirasol-nejm-2023" ;
  schema:name "MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer"@en ;
  schema:description "The antibody-drug conjugate mirvetuximab soravtansine lengthened survival compared with chemotherapy in platinum-resistant ovarian cancer with high folate receptor alpha expression, the first drug ever to do so in this setting."@en ;
  schema:url <https://onco.cc/key-papers/paper-mirasol-nejm-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2309169>, <https://pubmed.ncbi.nlm.nih.gov/38055253/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2309169> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Moore KN, Angelergues A, Konecny GE, et al." ;
  onco:cancers <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>, <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/> ;
  onco:drugs <https://onco.cc/drugs/mirvetuximab-soravtansine/> ;
  onco:trials <https://onco.cc/trials/mirasol/> ;
  onco:journals <https://onco.cc/journals/nejm/> .